632 related articles for article (PubMed ID: 19576345)
1. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
[TBL] [Abstract][Full Text] [Related]
3. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
4. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid for risk stratification of patients with coronary artery disease.
Brodov Y; Chouraqui P; Goldenberg I; Boyko V; Mandelzweig L; Behar S
Cardiology; 2009; 114(4):300-5. PubMed ID: 19776568
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
8. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
9. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes.
Foussas SG; Zairis MN; Lyras AG; Patsourakos NG; Tsirimpis VG; Katsaros K; Beldekos DJ; Handanis SM; Mytas DZ; Karidis KS; Tselioti PG; Prekates AA; Ambrose JA
Am J Cardiol; 2005 Aug; 96(4):533-7. PubMed ID: 16098307
[TBL] [Abstract][Full Text] [Related]
10. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease.
Kazemi-Bajestani SM; Ghayour-Mobarhan M; Ebrahimi M; Moohebati M; Esmaeili HA; Ferns GA
Clin Lab; 2007; 53(1-2):49-56. PubMed ID: 17323825
[TBL] [Abstract][Full Text] [Related]
12. High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease.
Jánoskuti L; Förhécz Z; Hosszúfalusi N; Kleiber M; Walentin S; Bálint O; Duba J; Rugonfalvi-Kiss S; Romics L; Karádi I; Füst G; Prohászka Z
Eur J Clin Invest; 2005 Feb; 35(2):104-11. PubMed ID: 15667581
[TBL] [Abstract][Full Text] [Related]
13. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy.
Vitale C; Cerquetani E; Wajngarten M; Leonardo F; Silvestri A; Mercuro G; Fini M; Ramires JA; Rosano GM
Ital Heart J; 2003 Sep; 4(9):627-32. PubMed ID: 14635381
[TBL] [Abstract][Full Text] [Related]
14. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease.
Ikonomidis I; Lekakis J; Revela I; Andreotti F; Nihoyannopoulos P
Eur Heart J; 2005 Aug; 26(16):1618-24. PubMed ID: 15800017
[TBL] [Abstract][Full Text] [Related]
15. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
[TBL] [Abstract][Full Text] [Related]
16. Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease.
Falcone C; Minoretti P; D'Angelo A; Buzzi MP; Coen E; Emanuele E; Aldeghi A; Olivieri V; Geroldi D
Eur J Clin Invest; 2006 Apr; 36(4):211-7. PubMed ID: 16620281
[TBL] [Abstract][Full Text] [Related]
17. [Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?].
Kiliç T; Ural E; Oner G; Sahin T; Kiliç M; Yavuz S; Kanko M; Kahraman G; Bildirici U; Berki KT; Ural D
Anadolu Kardiyol Derg; 2009 Aug; 9(4):280-9. PubMed ID: 19666429
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease.
Papa A; Emdin M; Passino C; Michelassi C; Battaglia D; Cocci F
Clin Chim Acta; 2008 Sep; 395(1-2):27-31. PubMed ID: 18498767
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease.
Musicant SE; Taylor LM; Peters D; Schuff RA; Urankar R; Landry GJ; Moneta GL
J Vasc Surg; 2006 Apr; 43(4):772-80; discussion 780. PubMed ID: 16616235
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.
Ioachimescu AG; Brennan DM; Hoar BM; Hazen SL; Hoogwerf BJ
Arthritis Rheum; 2008 Feb; 58(2):623-30. PubMed ID: 18240236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
